Neumora Therapeutics

NMRA

Market cap $280M

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&D Day on Monday, October 27, 2025, at 8:00 a.m.

WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September.

Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Daljit Singh Aurora - Corporate Participant Chief Operationg & Development officer - Corporate Participant Helen Rubinstein - Head of Investor Relations Joshua Pinto - President Michael Lee Milligan - CFO & Principal Accounting Officer Nicholas Brandon - Chief Scientific Officer Paul L. Berns - Chairman & CEO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division Douglas Dylan Tsao - H.C.

Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most significant news was a reduction in both research and development spending and overall net loss, while the company advanced multiple programs in its clinical pipeline.

Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period with up to six clinical data readouts in patients over the next 18 months, including Phase 3 data for navacaprant in major depressive disorder (MDD) and Phase 1b data for NMRA-511 in Alzheimer's disease agitation Strong financial position with $217.6 million in cash, cash equivalents and marketable securities expected to support operations into 2027 Company to host conference call today at 4:30 p.m. ET WATERTOWN, Mass.

WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update.

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861 in healthy adult participants and adults with stable schizophrenia.

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders.

NEW YORK , May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.

Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q1 2025 Results Conference Call May 12, 2025 4:30 PM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Mike Milligan - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Yatin Suneja - Guggenheim Graig Suvannavejh - Mizuho Securities John Boyle - William Blair Operator Ladies and gentlemen, thank you for standing by.